BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKinsey
Chinese Patent Office
QuintilesIMS
Express Scripts
Julphar
Baxter
Fish and Richardson
Covington
Healthtrust

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,344,212

« Back to Dashboard

Summary for Patent: 6,344,212
Title: Method of providing sustained analgesia with buprenorphine
Abstract:A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
Inventor(s): Reder; Robert F. (Greenwich, CT), Kaiko; Robert F. (Weston, CT), Goldenheim; Paul D. (Wilton, CT)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:09/756,419
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 6,344,212

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,344,212

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 336212 ➤ Subscribe
Austria 538765 ➤ Subscribe
Austria 556682 ➤ Subscribe
Australia 2004218685 ➤ Subscribe
Australia 2008261134 ➤ Subscribe
Australia 2012244363 ➤ Subscribe
Australia 2013204227 ➤ Subscribe
Australia 2925402 ➤ Subscribe
Australia 6184198 ➤ Subscribe
Australia 743071 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Department of Justice
Fuji
US Army
Medtronic
Julphar
Covington
AstraZeneca
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot